unknown
Stage
About
Akero Therapeutics develops novel therapies for metabolic diseases, focusing on treatments for metabolic dysfunction-associated steatohepatitis (MASH) with its investigational drug efruxifermin (EFX).
Explore Akero's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.